Dalian BIO-CHEM Company Limited (SHA:603360)
China · Delayed Price · Currency is CNY 19.40
-0.61 (-3.05%)
Jun 11, 2026, 3:00 PM CST
Dalian BIO-CHEM Company Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,486 | 1,712 | 1,264 | 1,054 | 1,253 | 995.18 |
Other Revenue | 12.41 | 12.41 | 6.83 | 11.3 | 3.32 | 11.08 |
| 1,498 | 1,724 | 1,271 | 1,066 | 1,257 | 1,006 | |
Revenue Growth (YoY) | 5.38% | 35.66% | 19.25% | -15.20% | 24.88% | 34.25% |
Cost of Revenue | 950.75 | 1,104 | 714.4 | 520.77 | 616.03 | 556.52 |
Gross Profit | 547.56 | 620.1 | 556.36 | 544.89 | 640.63 | 449.74 |
Selling, General & Admin | 162.91 | 171.93 | 111.16 | 120.52 | 132.2 | 91.52 |
Research & Development | 84.28 | 84.2 | 49.65 | 38.98 | 47.09 | 40.02 |
Other Operating Expenses | -1.64 | 0.74 | 10.62 | 10.37 | 14.93 | 9.17 |
Operating Expenses | 239.73 | 249.63 | 178.68 | 168.44 | 195.05 | 144.8 |
Operating Income | 307.83 | 370.46 | 377.68 | 376.44 | 445.58 | 304.93 |
Interest Expense | -37.47 | -30.26 | -6.7 | -3.92 | -3.72 | -11.77 |
Interest & Investment Income | - | 11.82 | 32.26 | 19.12 | 3.55 | 3.75 |
Currency Exchange Gain (Loss) | -4.3 | -4.3 | 8.4 | 6.42 | 17.15 | -0.47 |
Other Non Operating Income (Expenses) | 5.33 | -4.16 | -17.9 | -13.69 | -0.63 | -0.89 |
EBT Excluding Unusual Items | 271.4 | 343.57 | 393.74 | 384.37 | 461.93 | 295.55 |
Gain (Loss) on Sale of Investments | 1.18 | 0.4 | 53.45 | 0.01 | -7.57 | 0.59 |
Gain (Loss) on Sale of Assets | -0.43 | 0.17 | - | - | 0.07 | - |
Asset Writedown | -0.14 | -0.06 | -0.26 | -0.11 | -0.26 | -0.97 |
Legal Settlements | - | - | - | - | -0.12 | -10 |
Other Unusual Items | 4.97 | 5 | 3.27 | 1.5 | 7.38 | 6.87 |
Pretax Income | 281.47 | 353.57 | 450.2 | 385.78 | 461.43 | 292.04 |
Income Tax Expense | 36.64 | 46.48 | 52.82 | 57.4 | 58.87 | 41.55 |
Earnings From Continuing Operations | 244.83 | 307.09 | 397.38 | 328.38 | 402.57 | 250.49 |
Minority Interest in Earnings | -72.34 | -97.32 | -5.62 | - | - | - |
Net Income | 172.49 | 209.77 | 391.76 | 328.38 | 402.57 | 250.49 |
Net Income to Common | 172.49 | 209.77 | 391.76 | 328.38 | 402.57 | 250.49 |
Net Income Growth | -50.80% | -46.45% | 19.30% | -18.43% | 60.71% | 12.96% |
Shares Outstanding (Basic) | 686 | 699 | 700 | 697 | 692 | 687 |
Shares Outstanding (Diluted) | 686 | 699 | 700 | 697 | 692 | 694 |
Shares Change (YoY) | -1.57% | -0.05% | 0.43% | 0.64% | -0.30% | -3.01% |
EPS (Basic) | 0.25 | 0.30 | 0.56 | 0.47 | 0.58 | 0.36 |
EPS (Diluted) | 0.25 | 0.30 | 0.56 | 0.47 | 0.58 | 0.36 |
EPS Growth | -50.01% | -46.43% | 18.80% | -18.95% | 61.20% | 16.46% |
Free Cash Flow | 538.7 | 510.03 | 88.07 | 322.33 | 345.62 | -49.58 |
Free Cash Flow Per Share | 0.79 | 0.73 | 0.13 | 0.46 | 0.50 | -0.07 |
Dividend Per Share | - | - | 0.600 | 0.306 | 0.292 | - |
Dividend Growth | - | - | 96.01% | 4.97% | - | - |
Gross Margin | 36.55% | 35.97% | 43.78% | 51.13% | 50.98% | 44.69% |
Operating Margin | 20.54% | 21.49% | 29.72% | 35.33% | 35.46% | 30.30% |
Profit Margin | 11.51% | 12.17% | 30.83% | 30.81% | 32.04% | 24.89% |
Free Cash Flow Margin | 35.95% | 29.59% | 6.93% | 30.25% | 27.50% | -4.93% |
EBITDA | 406.72 | 463.34 | 446.49 | 440.08 | 516.59 | 353.15 |
EBITDA Margin | 27.15% | 26.88% | 35.13% | 41.30% | 41.11% | 35.10% |
D&A For EBITDA | 98.89 | 92.88 | 68.81 | 63.64 | 71.01 | 48.22 |
EBIT | 307.83 | 370.46 | 377.68 | 376.44 | 445.58 | 304.93 |
EBIT Margin | 20.54% | 21.49% | 29.72% | 35.33% | 35.46% | 30.30% |
Effective Tax Rate | 13.02% | 13.15% | 11.73% | 14.88% | 12.76% | 14.23% |
Revenue as Reported | 1,498 | 1,724 | 1,271 | 1,066 | 1,257 | 1,006 |
Advertising Expenses | - | 1.34 | 0.22 | 0.65 | 0.14 | 0.03 |